Insights On CONTRACT PHARMA MANUFACTURING
-
Best Practices To Adapt And Improve Quality Control Programs For CGTs
5/8/2024
Cell and gene therapies require adaptive and advanced assays for characterization and safety assessments; in many instances, the assays historically used for biologics must diversify to accommodate them.
-
Overcome The Challenges Of Designing A QC Program For New Modalities
5/8/2024
Stringent QC release testing throughout biologic production, as mandated by global health authorities, ensures product safety and quality through robust evaluations of identity, purity, potency, and critical quality attributes.
-
6 Key Questions When Selecting Your Cell Banking Manufacturing Partner
5/8/2024
Evaluating a potential cell banking partner's experience, testing capabilities, and approach to material management can help guarantee the quality and consistency of your therapeutic cells.
-
Treating Deficiencies In Employee Training And Mentorship
5/3/2024
Investing in employee training and development is not just beneficial for the employees. It also contributes significantly to the organization’s success and competitive advantage.
-
Advantages Of Cas9 mRNA For Gene Editing
4/26/2024
Discover why Cas9 mRNA is the preferred choice for precise gene editing, offering efficient delivery, transient expression, and flexible targeting.
-
The Synergistic Role Of Drug Safety In Clinical Trial Operations
4/25/2024
Delve into the significance of adept interpersonal leadership within your drug safety program, shedding light on the operational and financial benefits that stem from fostering a collaborative environment.
-
AAV Analytics: Key Considerations When Developing A Clinical Program
4/25/2024
Finding partners with the necessary skills to optimize AAV processes is crucial for minimizing risk. Explore key considerations for advancing your therapy from concept to commercialization.
-
The Critical Role Of Comparative Analytical Assessments
4/25/2024
Utilize our expert analytical testing services to unlock the potential of biosimilars and bring cost-effective treatments to market faster.
-
Identify And Quantify AAV Fill States Using Analytical Centrifugation
4/24/2024
Purified AAVs are prepared as a variety capsid species. To ensure gene therapy safety and efficacy, it is crucial to characterize and quantify those species.
-
De-Risking The Aseptic Drug-Filling Process And Optimizing Production
4/17/2024
Aseptic drug-filling poses significant risks for manufacturers that can increase costs and timelines. Leveraging proven expertise and efficiency can ensure the production of safe, efficacious products.